by Madaline Spencer | Jun 19, 2025
Salomon Manier, MD, PhD, Associate Professor of Hematology at Lille University Hospital in France, discusses results from a phase 1b clinical trial evaluating linvoseltamab combination therapy in patients with relapsed/refractory multiple myeloma (MM). ...
by Madaline Spencer | Jun 18, 2025
The U.S. Food and Drug Administration (FDA) has approved Andembry (garadacimab) for the treatment of hereditary angioedema (HAE) in patients ages 12 years and older. Hereditary Angioedema HAE is a rare condition characterized by recurrent episodes of severe...
by Madaline Spencer | Jun 18, 2025
Leticia Orsatti, MD, Vice President of Clinical Development and Medical Affairs at Boehringer Ingelheim, discusses results from clinical trials examining the safety and efficacy of nerandomilast to treat patients with idiopathic pulmonary fibrosis (IPF) or progressive...
by Madaline Spencer | Jun 17, 2025
Deb Jennings, Head of North America Patient Services Operations at Kyowa Kirin, discusses evolving policy landscapes for rare disease access. In a panel discussion at the 2025 World Orphan Drug Congress, Ms. Jennings explained the volatility of the...
by Madaline Spencer | Jun 16, 2025
Katie Niemeyer, patient advocate, discusses her experience with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). SJS/TEN is a very severe reaction that causes skin tissue to die and detach. SJS and TEN previously were thought to be separate...
